We aimed to identify prognostic factors associated with progression-free survival (PFS) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with sorafenib. We investigated 177 patients, including 116 who received sorafenib as first-line therapy, using the Cox regression model. During a median follow-up period of 19.2 months, the PFS and OS were 6.4 and 32.6 months among all patients and 7.4 months and undetermined for first-line sorafenib-treated patients, respectively. Clinical T3-4 stage (hazard ratio [HR] 2.56) and a primary tumor size >7 cm (HR 0.34) were significant prognostic factors for PFS among all patients, as were tumor size >7 cm (HR 0.12), collecting system invasion (HR 5.67), and tumor necrosis (HR 4.11) for OS (p < 0.05). In first-line sorafenib-treated patients, ≥4 metastatic lesions (HR 28.57), clinical T3-4 stage (HR 4.34), collecting system invasion (univariate analysis HR 2.11; multivariate analysis HR 0.07), lymphovascular invasion (HR 13.35), and tumor necrosis (HR 6.69) were significant prognosticators of PFS, as were bone metastasis (HR 5.49) and clinical T3-4 stages (HR 4.1) for OS (p < 0.05). Our study thus identified a number of primary tumor-related characteristics as important prognostic factors in sorafenib-treated mRCC patients.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
BioMed research international. 2017 Feb 07 [Epub]
Sung Han Kim, Sohee Kim, Byung-Ho Nam, Sang Eun Lee, Choung-Soo Kim, Ill Young Seo, Tae Nam Kim, Sung-Hoo Hong, Tae Gyun Kwon, Seong Il Seo, Kwan Joong Joo, Kanghyon Song, Cheol Kwak, Jinsoo Chung
Departments of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Republic of Korea., Division of Cancer Epidemiology and Prevention, Research Institute and Hospital, National Cancer Center, Biometric Research Branch, Goyang, Republic of Korea., Department of Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea., Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Department of Urology, Institute of Wonkwang Medical Science, Wonkwang University School of Medicine, Iksan, Republic of Korea., Department of Urology, Pusan National University Hospital, Busan, Republic of Korea., Department of Urology, Seoul St. Mary's Hospital, The Catholic University, Seoul, Republic of Korea., Department of Urology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea., Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Department of Urology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Department of Urology, Korea Cancer Center Hospital, Seoul, Republic of Korea., Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea.